FDA approves Bayer/Onyx kidney cancer drug

Share this article:
Bayer announced today that it has won FDA approval for its Nexavar (sorafenib) advanced kidney cancer drug, co-developed with Onyx Pharmaceuticals.
Nexavar is the first FDA-approved product for kidney cancer in more than a decade, the agency said.
Prior to the approval, Bayer said it did not expect regulatory approval for the drug until the first half of 2006. Bayer is expected to begin shipping Nexavar, primarily to specialty pharmacies, within the next 24 hours.
"The FDA approval of Nexavar is a crucial step for patients with advanced kidney cancer therapy," chief executive Werner Wenning said in a statement. " . . . Thanks to the rapid granting of approval, we will now be able to make this urgently needed product available earlier than planned."
According to Bayer, Nexavar has been shown to double "progression-free" survival in patients with kidney cancer.
Share this article:

Email Newsletters

More in Business Briefs

Illumina inks deal with J&J, AstraZeneca, Sanofi

The goal is to develop companion diagnostics to match patients with cancer treatments.

Abbott deal highlights inversion inaction

Political furor over the recent spate of tax inversions is having little influence on how the government chooses its partners.

Allergan reported to seek out Salix deal

The Wall Street Journal says the deal would add "another layer of intrigue" to the Allergan-Valeant hostilities.